GlassScriptPhysician profile
Trung Dinh Tran
NPI 1871571687
$2,636.85
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $46.50 · 2021: $398 · 2022: $566 · 2023: $372 · 2024: $438 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $514.28 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $406.27 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $193.25 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $186.14 | 2019-2025 | Bexsero |
| Cranial Technologies, INC | $159.34 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $155.40 | 2021-2025 | Qelbree |
| Neos Therapeutics, LP | $127.56 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $111.05 | 2022-2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $110.01 | 2021-2023 | |
| Grt US Holding, INC. | $90.00 | 2021-2022 | |
| Sanofi Pasteur INC. | $75.41 | 2021-2025 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Pfizer INC. | $68.82 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2022 | |
| Genentech USA, INC. | $49.07 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.49 | 2022-2023 | Gardasil 9, Rotateq, Vaxneuvance |
| Alk-Abello, INC | $44.47 | 2025 | Neffy, Grastek, Odactra |
| Abbvie INC. | $31.82 | 2022 | |
| Sobi, INC | $27.27 | 2023 | |
| Seqirus USA INC | $22.93 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2019 | |
| Kaleo, INC. | $19.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.25 | 2025 | |
| Verrica Pharmaceuticals INC. | $19.03 | 2024 | Ycanth |
| Shire North American Group INC | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.